SCRI-CAR19v3
Phase 1Biologic
SCRI-CAR19v3 is one of 9 biologic programs targeting Autoimmunity. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Autoimmunity
#DrugCompanyPhaseTrials
1Skyrizi
AbbVieApproved
Trexall
Alnylam PharmaceuticalsPhase 3
Biological Collection
AAssistance Publique - Hôpitaux de Paris
Approved
Ocrevus
RochePhase 2
Proleukin
IIovance Biotherapeutics, Inc.
Phase 2
Prednisone and Aspirin
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Approved
BRIUMVI
TTG Therapeutics, Inc.
Phase 2
TOL-3021
TTolerion, Inc.
Phase 2
SCRI-CAR19v3
SSeattle Children's Hospital
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SCRI-CAR19v3. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- SSeattle Children's Hospital